- Home
- PDD vs JNJ Comparison
PDD vs JNJ Comparison
Compare PDD & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDD | JNJ |
|---|---|---|
| Founded | 2015 | 1886 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0B | 505.3B |
| IPO Year | 2018 | 1944 |
Fundamental Metrics
Financial Performance| Metric | PDD | JNJ |
|---|---|---|
| Price | $104.73 | $218.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 15 |
| Target Price | $137.55 | ★ $209.27 |
| AVG Volume (30 Days) | ★ 9.3M | 7.9M |
| Earning Date | 11-18-2025 | 01-21-2026 |
| Dividend Yield | N/A | ★ 2.38% |
| EPS Growth | N/A | ★ 71.26 |
| EPS | 9.68 | ★ 10.35 |
| Revenue | $58,790,822,784.00 | ★ $92,149,000,000.00 |
| Revenue This Year | $10.73 | $6.63 |
| Revenue Next Year | $14.94 | $5.49 |
| P/E Ratio | ★ $11.03 | $21.13 |
| Revenue Growth | ★ 12.48 | 5.08 |
| 52 Week Low | $87.11 | $141.50 |
| 52 Week High | $139.41 | $220.11 |
Technical Indicators
Market Signals| Indicator | PDD | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 31.26 | 67.46 |
| Support Level | $106.10 | $203.85 |
| Resistance Level | $125.36 | $220.11 |
| Average True Range (ATR) | 3.25 | 3.57 |
| MACD | -1.15 | 1.13 |
| Stochastic Oscillator | 11.45 | 89.01 |
Price Performance
Historical ComparisonAbout PDD PDD Holdings Inc.
PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.